Actively Recruiting
Identification of Therapeutic Targets in Metastatic Gastric Cancer
Led by Chinese University of Hong Kong · Updated on 2026-04-24
100
Participants Needed
1
Research Sites
519 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.
CONDITIONS
Official Title
Identification of Therapeutic Targets in Metastatic Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 80 years old
- Performance status (WHO) of 2 or less
- Diagnosed with gastric adenocarcinoma with lymph node or distant metastases, including liver, lung, bone, or peritoneum
- Patients with isolated ovarian metastasis may be included
- Receiving or scheduled to receive neoadjuvant or palliative chemotherapy, targeted therapy, or immunotherapy
- Able to provide written consent before starting treatment
You will not qualify if you...
- Not receiving neoadjuvant or palliative chemotherapy, targeted therapy, or immunotherapy
- Pregnant or breastfeeding
- Patients with irreversible coagulation disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong, 0000
Actively Recruiting
Research Team
S
Shannon Melissa Chan, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here